XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS ...Middle East

SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals...

Read More Details
Finally We wish PressBee provided you with enough information of ( XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS )

Also on site :

• ‘Up close and personal’ – Taylor Swift and Travis Kelce share intimate date night as onlooker gives insight into romance
• Bianca Censori Makes Major Career Move After Dropping Jaws With See-Through Outfit
• Exactly How Many Times a Week To Walk To Improve Your Heart Health, According to Cardiologists